Although the rates of level 2 and 3 hypoglycaemic events were not significantly higher than those experienced with once-daily insulins, at least for type 2 diabetes, it should be noted that, in all Phase III studies of type 2 diabetes, clinically relevant hypoglycaemic episodes (i.e. blood glucose <3 mmol/l) were frequently numerically higher in participants treated with icodec than in those treated with once-daily insulins [23, 26]. The gene discussed is INS; the disease is type 2 diabetes mellitus.